Effects of nifedipine GITS and diuretics in isolated systolic hypertension - A subanalysis of the INSIGHT study

Blood Pressure

Volumn 13, Issue 5, 2004, Pages 310-315

  Mancia, Guiseppe ^a   Ruilope, Luis M ^b   Palmer, Christopher R ^c   Brown, Morris ^c   Castaigne, Alain ^d   de Leeuw, Peter ^e   Rosental, Talma ^f   Wagener, Gilbert ^g  

^a SAN GERARDO HOSPITAL   (Italy)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d HENRI MONDOR HOSPITAL   (France)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f TEL AVIV UNIVERSITY   (Israel)

^g BAYER PHARMA AG   (Germany)

Author keywords

Diuretics; Isolated systolic hypertension; Nifedipine

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIHYDROPYRIDINE; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LISINOPRIL; NIFEDIPINE; NITRENDIPINE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HYPERTENSION;

AGED; AGED, 80 AND OVER; AMILORIDE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DOSAGE FORMS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; PROSPECTIVE STUDIES;

EID: 9244234310     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050410022954     Document Type: Article

References (22)

1. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37: 869-74.
2. Kannel WB. Prevalence and implications of uncontrolled systolic hypertension. Drugs Aging 2003; 20: 277-86.
3. Staessen J, Amery A, Fagard R. Isolated systolic hypertension in the elderly. J Hypertens 1990; 8: 393-405.
4. Kannel WB. Coronary risk factors: an overview. In Willerson JT, Cohn JN, editors. Cardiovascular medicine. New York: Churchill Livingstone, 1995: 1809-28.
5. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823-9.
6. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255-64.
7. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-64.
8. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003; 12: 160-7.
9. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491-8.
10. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-72.
11. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ 1998; 317: 362-3.
12. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
13. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985; 291: 97-104.
14. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992; 304: 405-12.
15. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349-54.
16. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986; 293: 1145-51.
17. Sesso HD, Stampfer MJ, Rosner B, Hennekens CH, Gaziano JM, Manson JE, et al. Systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure as predictors of cardiovascular disease risk in Men. Hypertension 2000; 36: 801-7.
18. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-64.
19. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055-76.
20. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
21. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-15.
22. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.